Literature DB >> 3131494

An argument in support of cost-effectiveness analysis in oncology.

M Markman1.   

Abstract

Mesh:

Year:  1988        PMID: 3131494     DOI: 10.1200/JCO.1988.6.6.937

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Partial responses to antineoplastic drug therapy: what do they mean?

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  High technology drugs for cancer: the decision process for adding to a formulary.

Authors:  J L Glennie; D M Woloschuk; K W Hall
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

3.  Fair and effective resource allocation in cancer care: uncharted territory?

Authors:  J A Green; C Williams; A Cribb; B Brecher; M Evans
Journal:  Health Care Anal       Date:  1996-02

4.  The difficulty defining "benefit" of new antineoplastic strategies.

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

5.  Quality and cost in the palliative care of cancer.

Authors:  B W Hancock
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

6.  The cost of breast cancer recurrences.

Authors:  S F Hurley; R M Huggins; R D Snyder; J F Bishop
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.